Asset Details
Do you wish to reserve the book?
Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
Do you wish to request the book?
Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
2021
Overview
Vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been highly efficient in protecting against Coronavirus Disease 2019 (COVID-19). However, the emergence of viral variants that are more transmissible and, in some cases, escape from neutralizing antibody responses has raised concerns. Here, we evaluated recombinant protein spike antigens derived from wild-type SARS-CoV-2 and from variants B.1.1.7, B.1.351, and P.1 for their immunogenicity and protective effect in vivo against challenge with wild-type SARS-CoV-2 in the mouse model. All proteins induced high neutralizing antibodies against the respective viruses but also induced high cross-neutralizing antibody responses. The decline in neutralizing titers between variants was moderate, with B.1.1.7-vaccinated animals having a maximum fold reduction of 4.8 against B.1.351 virus. P.1 induced the most cross-reactive antibody responses but was also the least immunogenic in terms of homologous neutralization titers. However, all antigens protected from challenge with wild-type SARS-CoV-2 in a mouse model.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Antibodies, Neutralizing - immunology
/ Antibodies, Viral - immunology
/ Antigens
/ Control
/ COVID-19
/ COVID-19 - prevention & control
/ COVID-19 Vaccines - administration & dosage
/ COVID-19 Vaccines - immunology
/ Enzymes
/ Female
/ Homology
/ Medicine and health sciences
/ Mice
/ Proteins
/ Research and Analysis Methods
/ Severe acute respiratory syndrome
/ Severe acute respiratory syndrome coronavirus 2
/ Vaccines
/ Viruses
